rs567482892

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2

The NM_001009944.3(PKD1):​c.11682C>T​(p.Ser3894Ser) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0195 in 1,236,480 control chromosomes in the GnomAD database, including 308 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.012 ( 23 hom., cov: 33)
Exomes 𝑓: 0.021 ( 285 hom. )

Consequence

PKD1
NM_001009944.3 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:9

Conservation

PhyloP100: 1.86

Publications

4 publications found
Variant links:
Genes affected
PKD1 (HGNC:9008): (polycystin 1, transient receptor potential channel interacting) This gene encodes a member of the polycystin protein family. The encoded glycoprotein contains a large N-terminal extracellular region, multiple transmembrane domains and a cytoplasmic C-tail. It is an integral membrane protein that functions as a regulator of calcium permeable cation channels and intracellular calcium homoeostasis. It is also involved in cell-cell/matrix interactions and may modulate G-protein-coupled signal-transduction pathways. It plays a role in renal tubular development, and mutations in this gene cause autosomal dominant polycystic kidney disease type 1 (ADPKD1). ADPKD1 is characterized by the growth of fluid-filled cysts that replace normal renal tissue and result in end-stage renal failure. Splice variants encoding different isoforms have been noted for this gene. Also, six pseudogenes, closely linked in a known duplicated region on chromosome 16p, have been described. [provided by RefSeq, Oct 2008]
PKD1-AS1 (HGNC:56035): (PKD1 antisense RNA 1)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.53).
BP6
Variant 16-2091453-G-A is Benign according to our data. Variant chr16-2091453-G-A is described in ClinVar as Benign. ClinVar VariationId is 256908.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=1.86 with no splicing effect.
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.0119 (1768/148828) while in subpopulation NFE AF = 0.0194 (1293/66760). AF 95% confidence interval is 0.0185. There are 23 homozygotes in GnomAd4. There are 841 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 23 AD,AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
PKD1NM_001009944.3 linkc.11682C>T p.Ser3894Ser synonymous_variant Exon 42 of 46 ENST00000262304.9 NP_001009944.3

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
PKD1ENST00000262304.9 linkc.11682C>T p.Ser3894Ser synonymous_variant Exon 42 of 46 1 NM_001009944.3 ENSP00000262304.4 P98161-1

Frequencies

GnomAD3 genomes
AF:
0.0119
AC:
1768
AN:
148720
Hom.:
23
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00344
Gnomad AMI
AF:
0.0165
Gnomad AMR
AF:
0.00797
Gnomad ASJ
AF:
0.00205
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00270
Gnomad FIN
AF:
0.0169
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0194
Gnomad OTH
AF:
0.0107
GnomAD2 exomes
AF:
0.0179
AC:
126
AN:
7026
AF XY:
0.0156
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0286
Gnomad ASJ exome
AF:
0.00213
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.0342
Gnomad NFE exome
AF:
0.0267
Gnomad OTH exome
AF:
0.00943
GnomAD4 exome
AF:
0.0206
AC:
22388
AN:
1087652
Hom.:
285
Cov.:
32
AF XY:
0.0203
AC XY:
10666
AN XY:
524320
show subpopulations
African (AFR)
AF:
0.00263
AC:
52
AN:
19750
American (AMR)
AF:
0.0110
AC:
72
AN:
6560
Ashkenazi Jewish (ASJ)
AF:
0.00326
AC:
39
AN:
11974
East Asian (EAS)
AF:
0.0000534
AC:
1
AN:
18712
South Asian (SAS)
AF:
0.00138
AC:
57
AN:
41338
European-Finnish (FIN)
AF:
0.0185
AC:
445
AN:
24078
Middle Eastern (MID)
AF:
0.00320
AC:
9
AN:
2814
European-Non Finnish (NFE)
AF:
0.0227
AC:
20897
AN:
920796
Other (OTH)
AF:
0.0196
AC:
816
AN:
41630
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.509
Heterozygous variant carriers
0
1105
2210
3316
4421
5526
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
924
1848
2772
3696
4620
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0119
AC:
1768
AN:
148828
Hom.:
23
Cov.:
33
AF XY:
0.0116
AC XY:
841
AN XY:
72568
show subpopulations
African (AFR)
AF:
0.00343
AC:
141
AN:
41160
American (AMR)
AF:
0.00796
AC:
119
AN:
14948
Ashkenazi Jewish (ASJ)
AF:
0.00205
AC:
7
AN:
3418
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5100
South Asian (SAS)
AF:
0.00271
AC:
13
AN:
4804
European-Finnish (FIN)
AF:
0.0169
AC:
158
AN:
9368
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
292
European-Non Finnish (NFE)
AF:
0.0194
AC:
1293
AN:
66760
Other (OTH)
AF:
0.0106
AC:
22
AN:
2070
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
100
201
301
402
502
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
24
48
72
96
120
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0161
Hom.:
4
Bravo
AF:
0.0109

ClinVar

Significance: Benign
Submissions summary: Benign:9
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:4
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Apr 25, 2025
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Polycystic kidney disease, adult type Benign:2
Sep 25, 2018
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

May 30, 2017
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Oct 22, 2020
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 15772804, 17574468, 18837007, 22008521, 22383692, 24374109) -

Polycystic kidney disease Benign:1
-
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

The PKD1 p.Ser3894Ser variant was identified in 11 of 1112 proband chromosomes (frequency: 0.01) from individuals or families with ADPKD (Bataille 2011, Garcia-Gonzalez 2007, Rossetti 2012, Peltola 2005). The variant was also identified in dbSNP (ID: rs567482892) as “N/A” and the ADPKD Mutation Database (as likely neutral). This variant was identified in the 1000 Genomes Project in 21 of 5000 chromosomes (frequency: 0.004), the Exome Aggregation Consortium database (August 8, 2016) in 8 (1 homozygous) of 462 chromosomes (freq. 0.02) in the following populations: European in 5 of 40 chromosomes (freq. 0.13), Finnish in 1 of 2 chromosomes (freq. 0.5), Latino in 1 of 10 chromosomes (freq. 0.1), South Asian in 1 of 398 chromosomes (freq. 0.003), although this low number of observations and low frequency is not substantive enough to determine the prevalence of the variant in the general population and its relationship to disease. The p.Ser3894Ser variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. The variant occurs outside of the splicing consensus sequence and 3 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing. However, this information is not predictive enough to assume pathogenicity. In addition, the variant classified as a polymorphism by number of population and research studies (Bataille 2011, Garcia-Gonzalez 2007, Rossetti 2012, Peltola 2005). In summary, based on the above information, this variant meets our laboratory criteria to be classified as benign. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.53
CADD
Benign
5.9
DANN
Benign
0.91
PhyloP100
1.9
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Mutation Taster
=98/2
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs567482892; hg19: chr16-2141454; COSMIC: COSV99239592; COSMIC: COSV99239592; API